Ms Kiran Mazumdar-Shaw is a pioneering biotech entrepreneur, a healthcare visionary, a global influencer and a passionate philanthropist. She is a pioneer of India’s biotech industry and founder of Biocon.
Ms. Mazumdar-Shaw is the proud recipient of two of India’s highest civilian honours, the Padma Shri (1989) and the Padma Bhushan (2005). She was also honoured with the Order of Australia, Australia’s Highest Civilian Honour in January 2020. In 2016, she was conferred with the highest French distinction-Knight of the Legion of Honour.
She has been named as the winner of EY World Entrepreneur of the Year™ 2020 Award, which is a testimony to her entrepreneurial journey of over four decades. She has been ranked as one of the world’s top 20 inspirational leaders in the field of biopharmaceuticals by The Medicine Maker Power List 2020.
She holds key positions in various industry, educational, government and professional bodies globally. She has recently been appointed as the Vice-Chair of the Global Board of Directors of U.S.-India Business Council and has been serving as a member of the Advisory Council of the UK-India Business Council. She has been elected as a full-term member of the Board of Trustees of The Massachusetts Institute of Technology (MIT), USA and has been serving as a member of the prestigious USA based National Academy of Engineering (NAE).
She also serves on the Board of Infosys Ltd, Narayana Hrudayalaya Ltd and PureTech Health PLC.
Ms Mazumdar-Shaw holds a bachelor’s degree in science (Zoology Hons.) from Bangalore University and has earned a master’s degree in malting and brewing from Ballarat College, Melbourne University. She has been awarded with several honorary degrees from the Universities of repute globally.
Ms Mazumdar-Shaw believes in compassionate capitalism and is the first woman business leader from India to sign the Giving Pledge, an initiative of the Gates Foundation, committing to give the majority of her wealth to philanthropic causes.
She is very passionate about innovation and mentors many science-based start-ups.